In the complex field of cancer immunotherapy, one of the main obstacles is that many tumors create an immunosuppressive microenvironment that blocks the activity of T cells—even when immune checkpoint inhibitors like anti-PD-1 or anti-PD-L1 antibodies are used. A recent study published in Nature Communications presents an innovative strategy to overcome this barrier: using an ATR kinase inhibitor called ceralasertib, not merely as a cytotoxic agent, but as an immune system modulator capable of reprogramming the tumor environment to favor immunotherapy. This concept represents a significant conceptual evolution, where DNA damage-targeting therapies are no longer just cytotoxic tools but become powerful immunomodulatory agents.

ATR is a central kinase in the cellular response to replication stress and DNA damage. Its normal function is to pause the cell cycle to allow DNA repair before erroneous division occurs. By inhibiting this enzyme, ceralasertib intensifies DNA damage in tumor cells, but interestingly, it also triggers a series of events that profoundly affect the immune system. Researchers used multiple mouse cancer models, including MC38, CT26, and A20, applying an intermittent treatment regimen—seven days on the drug followed by seven days off—mirroring the schedule used in patients in the HUDSON clinical trial. This approach revealed that ceralasertib exerts its antitumor effect in a CD8+ T cell–dependent manner, not only through direct tumor cell death but also through reshaping the immune microenvironment.

During treatment phases, ceralasertib temporarily reduces T cell numbers within the tumor, likely due to its impact on actively replicating cells. However, once the drug is paused, T cells rapidly recover and reinfiltrate the tumor, now within a more favorable environment. This on-off cycling is essential: it prevents sustained immunosuppression and allows functional renewal of the T cell compartment, which is key for a durable immune response. This cycle of “reset and repopulate” appears fundamental to therapeutic success.

Deeper analyses, including mass cytometry (CyTOF) and single-cell RNA sequencing (scRNA-seq), revealed that ceralasertib reduces the population of exhausted CD8+ T cells—identified by high expression of PD-1, LAG3, ICOS and low interferon gamma production—and favors the presence of resting or less differentiated T cells. Furthermore, ceralasertib increased PD-1 expression on CD8+ and CD4+ T cells during recovery, which might seem counterintuitive, but in fact makes them more susceptible to PD-L1 blockade, explaining the synergy observed with combination therapy.

The tumor microenvironment itself was markedly transformed. Ceralasertib reduced the number of immunosuppressive cells like monocytic MDSCs and tumor-associated macrophages (TAMs), while enhancing the activation of dendritic cells (DCs)—critical for initiating T cell responses—by increasing their expression of MHC-I, MHC-II, CD40, and CD80. These changes were observed both in the tumor and in the spleen, suggesting a systemic immunomodulatory effect. At the molecular level, one of the most prominent events was the activation of the type I interferon (IFN-I) pathway, a cytokine family critical for immune cell activation and increased tumor immunogenicity.

What’s most compelling is that this interferon response was not just a correlation. The study included both loss- and gain-of-function experiments where IFN-I receptors (IFNAR1) were genetically blocked, completely eliminating ceralasertib’s therapeutic benefits. Conversely, mice engineered to express degradation-resistant IFNAR1 receptors exhibited markedly enhanced response to ceralasertib monotherapy, even at suboptimal doses. These findings clearly establish the ATR–IFN-I–immune response axis as essential for therapeutic efficacy.

This effect was also confirmed in tumor-free models, such as a chronic viral infection model using LCMV, where the combination of ceralasertib and anti-PD-L1 promoted expansion of CD8+ T cells specific for the viral antigen. Even in this context, ceralasertib boosted PD-1 expression and cytokine production such as IFN-γ and TNF-α, demonstrating that its immunomodulatory effects do not necessarily require the presence of a tumor. In human tumor cell lines, including lung cancer models, combining ceralasertib with IFN-β significantly enhanced antiproliferative effects, provided the cells were capable of responding to interferon signaling.

Figure 1. Schematic representation of how ATR inhibition by Ceralasertib transforms a cold tumor into a hot tumor. The treatment induces DNA damage and type I interferon signaling, promoting dendritic cell activation, CD8⁺ T cell infiltration, and tumor cell destruction.

Finally, the study included a genetically engineered mouse model (GEMM) of lung cancer, where ceralasertib treatment extended survival and activated IFN-I–related gene expression in tumors. These findings expand the potential impact of this strategy beyond transplantable models and into more clinically relevant settings.

Ceralasertib not only enhances DNA damage in tumor cells but also activates the immune system by triggering a wave of type I interferons that reshape the tumor microenvironment, eliminate immunosuppressive barriers, and reactivate T cells. What was once just a targeted therapy is now emerging as a dual-purpose immunotherapeutic tool. This work not only provides a mechanistic explanation for the clinical success observed in trials like HUDSON but also opens a new avenue for treating patients with tumors refractory to conventional immunotherapy. At a time when reversing immune resistance is a pressing challenge, this approach represents a transformative proposal in modern oncology.

Main Reference:

Hardaker, E. L., Sanseviero, E., Karmokar, A., Taylor, D., Milo, M., Michaloglou, C., Hughes, A., Mai, M., King, M., Solanki, A., Magiera, L., Miragaia, R., Kar, G., Standifer, N., Surace, M., Gill, S., Peter, A., Talbot, S., Tohumeken, S., Fryer, H., … Barry, S. T. (2024). The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nature communications, 15(1), 1700. https://doi.org/10.1038/s41467-024-45996-4

Other References:

Forment, J. V., & O’Connor, M. J. (2018). Targeting the replication stress response in cancer. Pharmacology & therapeutics, 188, 155–167. https://doi.org/10.1016/j.pharmthera.2018.03.005

Dillon, M. T., Bergerhoff, K. F., Pedersen, M., Whittock, H., Crespo-Rodriguez, E., Patin, E. C., Pearson, A., Smith, H. G., Paget, J. T. E., Patel, R. R., Foo, S., Bozhanova, G., Ragulan, C., Fontana, E., Desai, K., Wilkins, A. C., Sadanandam, A., Melcher, A., McLaughlin, M., & Harrington, K. J. (2019). ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(11), 3392–3403. https://doi.org/10.1158/1078-0432.CCR-18-1821

Feng, X., Tubbs, A., Zhang, C., Tang, M., Sridharan, S., Wang, C., Jiang, D., Su, D., Zhang, H., Chen, Z., Nie, L., Xiong, Y., Huang, M., Nussenzweig, A., & Chen, J. (2020). ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways. The EMBO journal, 39(14), e104036. https://doi.org/10.15252/embj.2019104036